[Federal Register: August 22, 2005 (Volume 70, Number 161)]
[Notices]               
[Page 48980]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22au05-108]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Registration

    By notice dated April 25, 2005, and published in the Federal 
Register on May 2, 2005, (70 FR 22704), Roche Diagnostics Operations 
Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, 
Indiana 46250, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
basic classes of controlled substances listed in Schedules I and II:

------------------------------------------------------------------------
                            Drug                               Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315)..........................            I
Tetrahydrocannabinol (7370)................................            I
Alphamethadol (9605).......................................            I
Phencyclidine (7471).......................................           II
Benzoylecgonine (9180).....................................           II
Methadone (9250)...........................................           II
Morphine (9300)............................................           II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Roche Diagnostics Operations Inc. to manufacture the listed basic 
classes of controlled substances is consistent with the public interest 
at this time. DEA has investigated Roche Diagnostics Operations Inc. to 
ensure that the company's registration is consistent with the public 
interest. The investigation has included inspection and testing of the 
company's physical security systems, verification of the company's 
compliance with state and local laws, and a review of the company's 
background and history. Therefore, pursuant to 21 U.S.C. 823, and in 
accordance with 21 CFR 1301.33, the above named company is granted 
registration as a bulk manufacturer of the basic classes of controlled 
substances listed.

    Dated: August 15, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-16568 Filed 8-19-05; 8:45 am]

BILLING CODE 4410-09-P